These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32392939)

  • 1. [Plasmablastic plasma cell myelomas with abnormal expression of CD3: report of a case].
    Zhang WY; Chen QR
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):492-494. PubMed ID: 32392939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow infiltration by plasmablastic neoplasm: plasmablastic myeloma or plasmablastic lymphoma?
    Eladl E; Chang H
    Blood; 2021 Mar; 137(9):1268. PubMed ID: 33661296
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease.
    Varricchio S; Pagliuca F; Travaglino A; Gallo L; Villa MR; Mascolo M
    J Cutan Pathol; 2019 Aug; 46(8):619-622. PubMed ID: 31025408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
    Ahn JS; Okal R; Vos JA; Smolkin M; Kanate AS; Rosado FG
    J Clin Pathol; 2017 Sep; 70(9):775-780. PubMed ID: 28249941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD31 expression in plasmacytic/plasmablastic lesions.
    Plocharczyk E; Wakely PE
    Ann Diagn Pathol; 2013 Dec; 17(6):498-501. PubMed ID: 24074836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmablastic lymphoma with aberrant expression of CD3 and CD4.
    Yan J; Sakhdari A
    Int J Lab Hematol; 2022 Aug; 44(4):692-693. PubMed ID: 35060329
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasmablastic transformation of plasma cell myeloma with heterotropic expression of CD3 and CD4: a case report.
    Mishra P; Kakri S; Gujral S
    Acta Clin Belg; 2017 Aug; 72(4):250-253. PubMed ID: 27374484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate.
    Tabata R; Tabata C; Uesugi H; Takei Y
    Int Immunopharmacol; 2019 Mar; 68():213-217. PubMed ID: 30658314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion.
    Yoshihara K; Yoshihara S; Matsuda I; Imado T; Matsuo S; Okada M; Shimizu Y; Hirota S; Fujimori Y
    Ann Hematol; 2020 Jun; 99(6):1405-1407. PubMed ID: 32125468
    [No Abstract]   [Full Text] [Related]  

  • 10. Plasmablastic lymphoma with unfavorable chromosomal abnormalities related to plasma cell myeloma: A borderline case between plasmablastic lymphoma and plasmablastic plasma cell myeloma.
    Aoyama Y; Tsunemine H; Kodaka T; Oda N; Matsuoka H; Itoh T; Takahashi T
    J Clin Exp Hematop; 2017; 57(1):37-39. PubMed ID: 28679965
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
    Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
    J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis.
    Harmon CM; Smith LB
    Arch Pathol Lab Med; 2016 Oct; 140(10):1074-8. PubMed ID: 27684979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoid neoplasms of the oral cavity with plasmablastic morphology-a case series and review of the literature.
    Bhattacharyya S; Bains APS; Sykes DL; Iverson BR; Sibgatullah R; Kuklani RM
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Dec; 128(6):651-659. PubMed ID: 31494113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasmablastic lymphoma: a clinicopathologic analysis of 11 cases with review of literature].
    Li F; Ding W; Zuo Z; Geng N; Yang H; Liu X; Wang J; Yao W; Liu W
    Zhonghua Bing Li Xue Za Zhi; 2016 Jan; 45(1):37-42. PubMed ID: 26791552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unusual case of myeloma.
    Tate C; McKinley M; Seymour L
    Pathology; 2018 Aug; 50(5):581-584. PubMed ID: 29921449
    [No Abstract]   [Full Text] [Related]  

  • 16. Peroxiredoxin I is differentially expressed in multiple myelomas and in plasmablastic lymphomas.
    Demasi AP; Magalhães MH; Furuse C; Araújo NS; Junqueira JL; Araújo VC
    Oral Dis; 2008 Nov; 14(8):741-6. PubMed ID: 18565146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmablastic lymphoma of bone marrow: Report of a rare case and immunohistochemistry based approach to the diagnosis.
    Sharma P; Sreedharanunni S; Koshy A; Prakash G; Sachdeva MUS; Malhotra P
    Indian J Pathol Microbiol; 2019; 62(1):107-110. PubMed ID: 30706870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
    Sher T; Miller KC; Lee K; Chanan-Khan A
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmablastic lymphoma of the oral cavity with breast recurrence: a case report.
    Samoon Z; Idrees R; Masood N; Ansari TZ
    BMC Res Notes; 2015 May; 8():180. PubMed ID: 25933603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extramedullary sarcomatoid variant of plasmablastic plasmacytoma.
    Majhi U; Sundersingh S; Murhekar K; Radha K
    J Cancer Res Ther; 2017; 13(6):1078-1079. PubMed ID: 29237987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.